The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.

REGISTER TODAY!



2025 NNECOS Spring Meeting

Cancer Care in 2025:
Considerations for the Care Team

Saturday, May 3, 2025

The Lodge at Spruce Park - Stowe, VT

Member registration rates begin at
just $75 through April 11th!

Distance-based Educational Travel Grants
of $75-$125 are available!


Learn More ~ Register Today!


ALL UPCOMING EDUCATIONAL OPPORTUNITIES

Lunchtime webinar Series

April 24, 2025 at 12:15pm

Putting Bispecific Antibodies into Practice
Yoni Resnick, PharmD

presented by Pfizer


SPRING MEETING

NNECOS Spring Meeting
May 3, 2025


OCN Review Course

NNECOS OCN Review Course

*NEW* May 16, 2025 - Nashua, NH*

September 15, 2025 - Portland, ME

*virtual option available

ANNUAL MEETING

NNECOS Annual Meeting
October 24-25, 2025

RESEARCH, PROJECT & PROGRAM FUNDING


Fall Submission Deadline - September 15th


Fall Submission Deadline

October 15th


Up to $4,000 to fund your educational program.

Rolling Application Deadline

NNECOS PATIENT PHILANTHROPY


Rolling Application Deadline

Up to $3,000 per grant


Rolling Application Deadline

Up to 125, $25 grocery/cards 


OTHER NEWS & INFORMATION

New! Patient Advisor!

NNECOS is delighted to announce the appointment of Tawnya McDonald as the inaugural NNECOS Patient/Caregiver Advisor. Tawnya will serve as a partner to the NNECOS Board of Directors, sharing feedback, generating ideas, and offering insight from a patient perspective, providing invaluable opinoins based on personal experience with aspects of care. 

NNECOS Classifieds

Visit the NNECOS Member Classifieds for more information about job listings from the following centers:

  • UVM Cancer Center, Larner College of Medicine 
  • Dartmouth Cancer Center

  • UVM Cancer Center

  • Beth Israel Lahey Health Exeter

Drug Shortages Sign On Letter

Looking Back!

Enjoy this wonderful interview with 3 of NNECOS' founding members!



SOCIAL MEDIA

 

Group Practice Members

Because your entire team benefits
from being a part of NNECOS!

Participate on a NNECOS Task Force


FDA Approvals & uPDATES

Latest FDA Approval

  • March 28 - FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication
  • March 26 - FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET
  • March 19 - FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)
  • February 14 - FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor
  • February 11 - FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma
  • February 11 - FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
  • January 27 - FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer
  • January 21 - FDA approves treosulfan with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation
  • January 17 - FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
  • January 16 - FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma
  • January 16 - FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer


Package/Label Updates


    Code Updates

    • Claim Issue Reported 1/8/25 impacting Part B providers in Jurisdiction JK and Jurisdiction J6 - Claims with healthcare common procedure coding system (HCPCS) G2211 with date of service (DOS) 1/1/2024-9/30/2024.

    • Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
    J1323- Injection, elranatamab-bcmm, 1 mg

    Other Updates


    Thank You Corporate Members!


    THANK YOU DIAMOND & PLATINUM CORPORATE MEMBERS

































    View the complete list of corporate members.

    Northern New England Clinical Oncology Society
    P.O. Box 643
    Sandown, NH 03873-0643
    Telephone (603) 887-1948
    info@nnecos.org

    This website brought to you by:


    Powered by Wild Apricot Membership Software